Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC-Reference-Cited by-同舟云学术

Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC

Published:2012-01-12 Issue:4 Volume:30 Page:200-205
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematol Oncol

Author:

Koren-Michowitz Maya¹,Volchek Yulia¹,Naparstek Elizabeth²,Gavish Israel³,Levi Itai⁴,Rowe Jacob M.⁵,Shimoni Avichai¹,Nagler Arnon¹

Affiliation:

1. Chaim Sheba Medical Center; Tel Hashomer; Israel

2. Sourasky Medical Center; Tel Aviv; Israel

3. Ha'emek Medical Center; Afula; Israel

4. Soroka Medical Center; Be'er Sheba; Israel

5. Rambam Medical Center; Haifa; Israel

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference22 articles.

1. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM);O'Brien;Blood,2008

2. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib;Deininger;Blood,2009

3. Chronic myeloid leukemia: an update of concepts and management recommendations of european LeukemiaNet;Baccarani;J Clin Oncol,2009

4. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification;Gorre;Science,2001

5. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib;Marin;J Clin Oncol,2010

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation;Cancer Chemotherapy and Pharmacology;2023-08-25

2. Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic‐phase chronic myeloid leukemia;Cancer;2022-10

3. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy;European Journal of Cancer;2021-11

4. Assessment of Oral Chemotherapy Nonadherence in Chronic Myeloid Leukemia Patients Using Brief Measures in Community Cancer Clinics: A Pilot Study;International Journal of Environmental Research and Public Health;2021-10-21

5. Therapeutic drug monitoring of imatinib in patients of chronic myeloid leukemia - Chronic phase;J PHARMACOL PHARMACO;2021